FDA Approval Insights: Olaparib in HRR-Mutant mCRPC

In our exclusive interview, Agarwal, who was also a member of the PROfound trial Global Steering Committee, discussed the approval of olaparib in HRR-mutant mCRPC, key efficacy and safety data from the PROfound trial, the importance of genomic sequencing in the metastatic setting, and ongoing research with PARP inhibitors in earlier lines of therapy.